Praluent's lower list price isn't yielding better sales yet

First quarter sales of Sanofi and Regeneron's Praluent missed Wall Street expectations by "a long shot," as one analyst put it, suggesting a recent price cut has yet to solve the broader challenges facing the cholesterol-lowering drug.